Proto Script Pharmaceutical

Proto Script Pharmaceutical EBIT Growth

The Year-over-Year EBIT Growth of Proto Script Pharmaceutical (PSCR) as of Oct 22, 2026 is 77.41 %. In the previous year, Year-over-Year EBIT Growth was 36.78 % — a change of 110.43% (higher).

EBIT Growth

77.41 %

YoY

110.43%

Last updated:

Year-over-Year EBIT Growth of Proto Script Pharmaceutical is 2016 77.41 % . Year-over-Year EBIT Growth of Proto Script Pharmaceutical was 2015 36.78 % . It decreases by 110.43% higher compared to the previous year.

The Proto Script Pharmaceutical EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2015
36.78 USD
Jan 1, 2016
77.41 USD
The Proto Script Pharmaceutical EBIT Growth history
YEAREBIT GrowthYoY
77.41 %+110.43%
36.78 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Proto Script Pharmaceutical Stock analysis

What does Proto Script Pharmaceutical do? Proto Script Pharmaceutical Corp is an American biotechnology company specializing in the development and manufacture of innovative, high-quality drugs. The company is focused on researching new breakthrough technologies in drug manufacturing to find potential cures and treat diseases. Their business model is based on producing medications that are highly effective and of high quality while also being cost-effective and patient-friendly. They collaborate closely with biotechnology companies and academic institutions to acquire the best technologies and develop effective and innovative drugs. They have products in the areas of neurology, endocrine health, and oncology. They have also entered into partnerships with other companies to expand and further develop their products. Overall, Proto Script Pharmaceutical Corp is a groundbreaking company in the biotechnology field with decades of experience in drug development and a commitment to improving the lives of millions of people worldwide. Proto Script Pharmaceutical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Proto Script Pharmaceutical stock

Year-over-Year EBIT Growth of Proto Script Pharmaceutical is 77.41 % in 2016.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Proto Script Pharmaceutical since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Proto Script Pharmaceutical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Proto Script Pharmaceutical

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Proto Script Pharmaceutical